GATA3 and cancer: GATA-3 was shown to be a biomarker of survival in dogs with malignant tumors (30), with 50.0% (8/16) of those that had a high GATA-3 expression (≥79.4%) surviving, while only 14.28% (2/14) of those with low expression (<794) survived, as shown in Figure 4B.